Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants

Yuli Lily Hsieh,C Robert Horsburgh Jr.,Ted Cohen,Jeffrey W Miller,Joshua A Salomon,Nicolas A Menzies
DOI: https://doi.org/10.1101/2024.10.09.24315062
2024-10-09
Abstract:Introduction: Host-response-based transcriptional signatures (HrTS) have been developed to identify "incipient tuberculosis (TB)". No study has reported the cost-effectiveness of HrTS for post-arrival migrant screening programs in low-incidence countries. Objectives: To assess the potential health impact and cost-effectiveness of HrTS for post-arrival TB infection screening among new migrants in the United States. Methods: We used a discrete event simulation model to compare four strategies: (1) no screening for TB infection or incipient TB; (2) 'IGRA-only', screen all with interferon gamma release assay (IGRA), provide TB preventive treatment for IGRA-positives; (3) 'IGRA-HrTS', screen all with IGRA followed by HrTS for IGRA-positives, provide incipient TB treatment for individuals testing positive with both tests; and (4) 'HrTS-only', screen all with HrTS, provide incipient TB treatment for HrTS-positives. We assessed outcomes over the lifetime of migrants entering the U.S. in 2019, assuming HrTS met the WHO Target Product Profile (TPP) optimal criteria. We conducted sensitivity analyses to evaluate the robustness of results. Results: The IGRA-only strategy dominated the HrTS-based strategies under both healthcare sector and societal perspectives, with an incremental cost-effectiveness ratio of $78,943 and $89,431 per quality-adjusted life-years (QALY) gained, respectively. This conclusion was robust to varying costs ($15 - 300) and characteristics of HrTS, and the willingness-to-pay threshold ($30,000 - 150,000/ QALY gained), but sensitive to the rate of decline in TB progression risk after U.S. entry. Conclusions: Our findings suggest that HrTS meeting the WHO TPP is unlikely to be a cost-effective component of post-arrival screening for migrants entering the U.S.
Health Economics
What problem does this paper attempt to address?
The paper aims to address the issue of evaluating the cost-effectiveness of host response-based transcriptomic biomarkers (HrTS) for screening latent tuberculosis infection (LTBI) or incipient tuberculosis (incipient TB) among new immigrants in the United States. Specifically, the study assesses the performance of these strategies in terms of health impact and cost-effectiveness by comparing four different screening strategies: no screening, using only interferon-gamma release assay (IGRA), using IGRA followed by HrTS testing for positive cases, and using only HrTS. The main finding of the study is that, from both the healthcare sector and societal perspectives, the strategy of using only IGRA is the most cost-effective. Even assuming that HrTS meets the World Health Organization (WHO) target product profile (TPP) optimal standards, strategies involving HrTS are still less cost-effective than using only IGRA. Additionally, sensitivity analysis shows that the conclusions are relatively robust to the cost of HrTS and the willingness-to-pay threshold but are sensitive to the rate of decline in the risk of tuberculosis progression after entry into the United States. In summary, the study aims to fill the current gap in the cost-effectiveness evaluation of HrTS as a post-immigration screening tool in low tuberculosis burden countries and concludes that even if HrTS meets WHO's optimal standards, it is unlikely to be a cost-effective screening method.